South Korea will allow Merck's Zilmax from June; Natco falls on Copaxone news; Pfizer suing Torrent over Viagra patents;

@FiercePharma: Gilead's Sovaldi triumph puts major hurt on payers' bottom lines. Story | Follow @FiercePharma

@TracyStaton: RT: Today is the first time in my 10 year data that larger cap biotech is trading at the same PE as US pharma. via @MarkSchoenebaum | Follow @TracyStaton

@EricPFierce: GSK attacks African market with combo of goodwill, R&D and plant projects. More | Follow @EricPFierce

@CarlyHFierce: Donald Trump's Twitter tirade blames vaccines for autism increase. News | Follow @CarlyHFierce

> In response to patient protests, Bayer is calling off plans to discontinue the supply of a hemophilia drug to South Korea. More

> Beginning in June, South Korea will allow sales of Merck's ($MRK) much-scrutinized Zilmax animal feed additive. Report

> A federal judge has rejected a request from Planned Parenthood and another clinic to block new Arizona regulations that would limit the use of abortion-inducing drugs. More

> Shares of India's Natco Pharma fell by as much as 19% on news that the U.S. Supreme Court would hear Teva's ($TEVA) appeal to restore patent protection on its multiple sclerosis drug Copaxone. Report

> Pfizer ($PFE) is suing Torrent Pharma, alleging that the Indian company breached its Viagra patents. More

> Baxter ($BAX) will continue to grow its biopharma manufacturing network after it splits into two separate companies in 2015. More

Medical Device News

@FierceMedDev: Covidien's CFO exercised his stock options near the company's 52 week high. Story | Follow @FierceMedDev

@MarkHFierce: Intuitive Surgical's latest da Vinci surgical robot could help it rebound from a challenging year. More | Follow @MarkHFierce

@MichaelGFierce: Wearable data-storing 'electronic skin' could deliver drugs for epilepsy, Parkinson's. Item | Follow @MichaelGFierce

@EmilyWFierce: New paper from researchers at Harvard sheds light on PMA supplement applications for medical devices. Article | Follow @EmilyWFierce

> IPO emigre Lombard Medical looks to raise $60M in a Nasdaq debut. News

> GE Healthcare unit recalls infant warmer systems in China. More

> China's Dehaier Medical continues its turnaround as revenue falls. Story

Biotech News

@FierceBiotech: Investors pump $200M into Intarcia's PhIII for once-yearly diabetes therapy. More | Follow @FierceBiotech

@JohnCFierce: Celgene doubles down on Forma with a $600M discovery deal tied to a buyout option. Article | Follow @JohnCFierce

@DamianFierce: On the way home from ACC14? Catch up on the state of the PCSK9 race with our in-depth feature. Read | Follow @DamianFierce

@EmilyMFierce: Committee finds 'scientific misconduct' in blockbuster stem cell papers. News | Follow @EmilyMFierce

> Foresite banks $300M to bet on late-stage biotechs. More

> Cubist's superbug drug clears FDA panel, lines up for Pfizer showdown. Piece

Biotech Research News

> Committee finds 'scientific misconduct' in blockbuster stem cell papers. News

> Anticancer compound could reverse symptoms of schizophrenia. More

> New molecule could provide relief for autoimmune, inflammatory diseases. Story

> Report: U.S. can do more to support global health R&D. Coverage

> Antioxidant could slow progression of Lou Gehrig's disease, extend lifespan. Article

> NIH opens largest U.S. neuroscience research center. Item

Pharma Manufacturing News

> Bayer will spend $138M to expand its Beijing plant. Story

> GSK sells Indonesia plant even as it boosts commitment there. Article

> Hospira settles investor suit tied to its manufacturing mess-ups. News

> GSK commits $165M toward 5 more plants in Africa. More

> FDA lets Fresenius import saline to help with shortage. Piece

> Regeneron resolves objections to its new Ireland plant. Item

And Finally... Veterinary oncologists are learning about the progression of breast cancer in humans through the treatment of tumors in shelter dogs. More (sub. req.)

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.